Transfer (epoetin alfa) is a man-made form of a protein that helps your body produce red blood cells. This protein may be reduced when you have kidney failure or use certain medications. When fewer red blood cells are produced, you can develop a condition called anemia.
Transfer is used to treat anemia caused by chemotherapy or chronic kidney disease, anemia caused by taking zidovudine to treat HIV (human immunodeficiency virus), or anemia due to other reasons.
Transfer is also used to reduce the need for red blood cell transfusions in people having certain types of surgery.
MODE OF ACTION:
Transfer has been shown to exert its effects by binding to the erythropoietin receptor (EpoR). It binds to the erythropoietin receptor on the red cell progenitor surface and activates a JAK2 signalling cascade. This initiates the STAT5, PIK3 and Ras MAPK pathways. This results in differentiation, survival and proliferation of the erythroid cell. It increases the number of developing erythroid precursors and accelerates the release of reticulocytes from the marrow
- CKD patients with symptomatic anemia
- Patients on dialysis
- Non-dialysis patients
- Pre-elective surgery patients
Initial: 50 to 100 Units/kg TIW; IV or SC increase dose by 25% if –
- Hemoglobin is < 10 g/dl and has not increased by 1 g/dl after 4 weeks of therapy
- Hemoglobin decreases below 10 g/dl
Reduce the dose by 25% when:
- Hemoglobin approaches 12 g/dl or
- Hemoglobin increases >1g/dl any 2-week period
This information is for registered medical practitioner only. Anyone other than medical practitioner should consult medical practitioner before using this product.